The Claim
In patients with atherosclerotic cardiovascular disease on statin therapy, a 1% greater reduction in LDL-C from baseline is associated with a 1% lower risk of major cardiovascular events, indicating a continuous, dose-response relationship between the magnitude of LDL-C lowering and cardiovascular risk reduction.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
For patients with atherosclerotic cardiovascular disease taking statins, every 1% decrease in LDL cholesterol from their starting level corresponds to a 1% decrease in the risk of major cardiovascular events.
See the scientific wording
In patients with atherosclerotic cardiovascular disease on statin therapy, a 1% greater reduction in LDL-C from baseline is associated with a 1% lower risk of major cardiovascular events, indicating a continuous, dose-response relationship between the magnitude of LDL-C lowering and cardiovascular risk reduction.
Lowering LDL cholesterol reduces the amount of fat building up inside artery walls, which stops plaques from growing and makes them less likely to rupture. This also reduces inflammation in the blood vessel walls, preventing clots that cause heart attacks and strokes.
What the research says
1 studyFor people with heart disease on statins, the more their bad cholesterol drops from where it started, the lower their risk of heart attack or stroke — even if their final cholesterol level is the same as someone else’s. A bigger drop means better protection.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.